|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN119876138A
(zh)
|
2014-11-14 |
2025-04-25 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
CA3193811A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
CN107249646B
(zh)
*
|
2014-12-16 |
2021-06-29 |
内布拉斯加大学董事会 |
用于青少年巴滕病的基因疗法
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US12138298B2
(en)
|
2017-01-30 |
2024-11-12 |
Brainvectis |
Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
|
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
JP7221275B2
(ja)
*
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
MX2020002148A
(es)
*
|
2017-08-25 |
2020-07-20 |
Ovid Therapeutics Inc |
Vectores adenoasociados recombinantes.
|
|
US20200263199A1
(en)
*
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
NZ763617A
(en)
*
|
2017-10-16 |
2026-01-30 |
Vigeneron Gmbh |
Aav vectors
|
|
EP3703716B1
(en)
|
2017-11-02 |
2026-03-25 |
California Institute of Technology |
Expression of neuropeptides
|
|
US11458129B2
(en)
|
2017-11-02 |
2022-10-04 |
California Institute Of Technology |
Neurokinin antagonists and uses thereof
|
|
US20190202866A1
(en)
*
|
2017-12-22 |
2019-07-04 |
William Marsh Rice University |
Viral nanoparticles and methods of use thereof
|
|
JP7430652B2
(ja)
|
2018-03-05 |
2024-02-13 |
ザ チルドレンズ メディカル センター コーポレーション |
蝸牛および前庭細胞に核酸を送達するための組成物および方法
|
|
US11608510B2
(en)
*
|
2018-03-30 |
2023-03-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
|
US20210363191A1
(en)
|
2018-04-03 |
2021-11-25 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
AU2019253700B2
(en)
*
|
2018-04-09 |
2025-08-14 |
Allen Institute |
Rescuing voltage-gated sodium channel function in inhibitory neurons
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
WO2019198084A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-aging compositions and methods of use
|
|
CA3096293A1
(en)
|
2018-04-27 |
2019-10-31 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy for cns degeneration
|
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
CN112703198B
(zh)
*
|
2018-07-11 |
2025-05-30 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
AU2019310459A1
(en)
|
2018-07-24 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
JP7695192B2
(ja)
|
2018-10-08 |
2025-06-18 |
アレン インスティテュート |
介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
AU2019373340B2
(en)
|
2018-10-29 |
2025-09-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
|
|
CN113395975A
(zh)
*
|
2018-11-20 |
2021-09-14 |
宾夕法尼亚州大学信托人 |
用于靶向血脑屏障的组合物和方法
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
EP3917945A4
(en)
*
|
2019-01-30 |
2023-02-08 |
The Broad Institute Inc. |
ADVANCED ADENO-ASSOCIATED VIRUS (AAVS) TARGETED DELIVERY SYSTEMS
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
KR20210130158A
(ko)
*
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
|
EP3923995A4
(en)
*
|
2019-02-15 |
2023-05-17 |
Allen Institute |
ARTIFICIAL EXPRESSION RECOMBINANTS FOR THE SELECTIVE MODULATION OF GENE EXPRESSION IN SELECTED NEURON CELL POPULATIONS
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
MX2021011701A
(es)
*
|
2019-03-28 |
2021-12-10 |
Massachusetts Gen Hospital |
Vectores adenoasociados fabricados por ingenieria (aav) para expresion transgenica.
|
|
AU2020271108A1
(en)
*
|
2019-04-11 |
2021-11-11 |
California Institute Of Technology |
Virus compositions with enhanced specificity in the brain
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
CN114127275A
(zh)
*
|
2019-04-30 |
2022-03-01 |
宾夕法尼亚州大学信托人 |
可用于治疗庞贝病的组合物
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020234363A2
(en)
|
2019-05-21 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
TW202122582A
(zh)
|
2019-08-26 |
2021-06-16 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
WO2021041489A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
GB201912863D0
(en)
*
|
2019-09-06 |
2019-10-23 |
Babraham Inst |
Novel method
|
|
GB201913974D0
(en)
*
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
CA3157523A1
(en)
*
|
2019-10-17 |
2021-04-22 |
Gong Chen |
Regenerating functional neurons for treatment of spinal cord injury and als
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
IL292264B2
(en)
*
|
2019-10-17 |
2025-10-01 |
Stridebio Inc |
aav transfer cassette
|
|
CA3159018A1
(en)
*
|
2019-11-19 |
2021-05-27 |
Michael W. O'CALLAGHAN |
Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
|
|
PH12022551247A1
(en)
*
|
2019-11-22 |
2023-11-13 |
Childrens Hospital Philadelphia |
Adeno-associated viral vector variants
|
|
AU2021206256A1
(en)
|
2020-01-10 |
2022-07-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
WO2021163357A2
(en)
|
2020-02-13 |
2021-08-19 |
Tenaya Therapeutics, Inc. |
Gene therapy vectors for treating heart disease
|
|
MY209860A
(en)
|
2020-02-13 |
2025-08-07 |
Tenaya Therapeutics Inc |
Gene therapy vectors for treating heart disease
|
|
IL297391A
(en)
|
2020-04-20 |
2022-12-01 |
Tenaya Therapeutics Inc |
An adeno-associated virus with an engineered capsid
|
|
CN112011571A
(zh)
*
|
2020-04-26 |
2020-12-01 |
辉大(上海)生物科技有限公司 |
一种用于治疗脊髓性肌萎缩的基因治疗药物
|
|
US20230173102A1
(en)
*
|
2020-04-28 |
2023-06-08 |
Genethon |
Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders
|
|
US20210403946A1
(en)
|
2020-04-29 |
2021-12-30 |
The Broad Institute, Inc. |
Machine learning accelerated protein engineering through fitness prediction
|
|
AU2021264061A1
(en)
*
|
2020-05-01 |
2022-12-01 |
Massachusetts Institute Of Technology |
Engineered central nervous system compositions
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
GB202011871D0
(en)
*
|
2020-07-30 |
2020-09-16 |
Cambridge Entpr Ltd |
Composition and method
|
|
BR112023001336A2
(pt)
|
2020-08-05 |
2023-02-14 |
Spacecraft Seven Llc |
Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
JP2023538519A
(ja)
|
2020-08-07 |
2023-09-08 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Ａａｖベクターを使用したプラコフィリン－２（ｐｋｐ２）遺伝子治療
|
|
US20230340041A1
(en)
|
2020-08-17 |
2023-10-26 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
EP4200408A1
(en)
|
2020-08-19 |
2023-06-28 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of rett syndrome
|
|
CA3192600A1
(en)
*
|
2020-08-21 |
2022-02-24 |
Capsida, Inc. |
Adeno-associated virus compositions having preferred expression levels
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
CA3193406A1
(en)
*
|
2020-09-21 |
2022-03-24 |
Asklepios Biopharmaceutical, Inc. |
Methods for treating neurological disease
|
|
WO2022066911A1
(en)
*
|
2020-09-23 |
2022-03-31 |
Seelos Therapeutics, Inc. |
Compositions and methods for inhibiting alpha-synuclein aggregation
|
|
CN112194706B
(zh)
*
|
2020-09-30 |
2022-03-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
WO2022079082A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
|
CA3201533A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4317440A4
(en)
*
|
2021-03-29 |
2025-05-14 |
Nanjing University |
Viral vector-based rna delivery system and use thereof
|
|
WO2022221421A2
(en)
*
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Aav compositions with high brain expression for treating mucopolysaccharidosis ii
|
|
JP2024515626A
(ja)
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
|
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
|
AU2022307365A1
(en)
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
US20240382617A1
(en)
*
|
2021-09-21 |
2024-11-21 |
Capsida Biotherapeutics, Inc. |
Virus compositions to efficiently target the nervous system and the lungs
|
|
MX2024004217A
(es)
|
2021-10-08 |
2024-06-26 |
Dyno Therapeutics Inc |
Variantes de cápside y métodos de uso de estas.
|
|
US20250235554A1
(en)
|
2021-10-25 |
2025-07-24 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
MX2024004936A
(es)
*
|
2021-11-02 |
2024-05-08 |
Voyager Therapeutics Inc |
Variantes de capsides de aav y sus usos.
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
CN114107231B
(zh)
*
|
2021-12-13 |
2023-08-18 |
重庆大学 |
实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN116554278A
(zh)
*
|
2022-01-30 |
2023-08-08 |
上海玮美基因科技有限责任公司 |
变异型腺相关病毒及其在疾病治疗中的应用
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
WO2023205397A1
(en)
*
|
2022-04-22 |
2023-10-26 |
The Children's Hospital Of Philadelphia |
Human ependyma-specific promoter and uses thereof
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023240236A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2024054864A1
(en)
|
2022-09-06 |
2024-03-14 |
Tenaya Therapeutics, Inc. |
Cardioprotective heart disease therapies
|
|
US20260085328A1
(en)
|
2022-09-08 |
2026-03-26 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
EP4615492A1
(en)
|
2022-11-08 |
2025-09-17 |
Ospedale San Raffaele S.r.l. |
Polynucleotide and vector
|
|
WO2024175604A1
(en)
|
2023-02-21 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
|
|
EP4676939A1
(en)
*
|
2023-03-09 |
2026-01-14 |
Agency for Science, Technology and Research |
Novel compositions of adeno-associated viruses engineered for enhanced tissue transduction and specificity
|
|
TW202502803A
(zh)
|
2023-03-10 |
2025-01-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法
|
|
CN121219020A
(zh)
|
2023-03-22 |
2025-12-26 |
圣拉斐尔医院有限责任公司 |
基因疗法
|
|
AU2024242380A1
(en)
*
|
2023-03-31 |
2025-11-06 |
Exegenesis Bio Singapore Pte. Ltd. |
Variant aav9 capsid proteins and uses thereof
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024229389A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4705488A1
(en)
*
|
2023-05-04 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024238807A2
(en)
|
2023-05-16 |
2024-11-21 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
AR133098A1
(es)
|
2023-06-29 |
2025-08-27 |
Univ Pennsylvania |
Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
|
|
WO2025021839A1
(en)
|
2023-07-25 |
2025-01-30 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat metabolic disorders
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025040166A1
(zh)
|
2023-08-23 |
2025-02-27 |
上海瑞宏迪医药有限公司 |
药物组合物及其用途
|
|
TW202525832A
(zh)
|
2023-08-31 |
2025-07-01 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(二)
|
|
CN117264912A
(zh)
*
|
2023-09-25 |
2023-12-22 |
中国科学院深圳先进技术研究院 |
一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025106874A1
(en)
*
|
2023-11-15 |
2025-05-22 |
Genzyme Corporation |
Methods of treating neurodegenerative disorders
|
|
WO2025157848A1
(en)
|
2024-01-23 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiib
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
WO2025186293A1
(en)
|
2024-03-06 |
2025-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Chmp2b mutants for use for treating infection
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|
|
WO2026064442A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|